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Background: As an adjunct to cholera preventionmeasures, WHO advises the use of oral cholera vaccine through
mass vaccination campaigns in high-risk areas and for vulnerable population groups. We assessed the feasibility
and acceptability of a mass vaccination campaign using 1) a predominantly fixed and 2) a mobile door-to-door
strategy.
Methods: Vaccination included administration of two doses (given 2 weeks apart) of oral cholera vaccine to indi-
viduals older than 1 year of age, in four refugee camps: Jamam, Doro, Batil and Gendrassa, and the host popu-
lation in Maban County, South Sudan, from December 2012 to February 2013.
Results: A total of 258 832 doses were administered to a population of 166 000 (126 000 refugees and 40 000
host population). The first round coverage for the refugees was above 84% for Doro, Jamam and Batil and 104%
for Gendrassa. The second dose reached the same coverage as the first dose. For the host population, the cover-
age for the first dose was above 90% in Doro and Jamam and 53% in Gendrassa and Batil. For the second round,
the coverage was above 79% in Doro and Jamam and above 70% in Batil and Gendrassa.
Conclusions: The vaccination of a large population in an emergency context proved to be feasible and acceptable
and achieved high coverage. This is encouraging and is a way forward for reducing cholera related morbidity and
mortality among vulnerable populations.
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Introduction
Cholera is an acute diarrheal disease, caused by the bacteria
Vibrio cholerae; in severe cases it can lead to death from dehydra-
tion and/or shock. In addition to appropriate clinical management
for suspected cholera cases, improvements in water and sanita-
tion facilities and community mobilization, WHO also advises
the use of oral cholera vaccine (OCV) through mass vaccination
campaigns (MVCs) in vulnerable population groups and in high-
risk areas for cholera.1 There are currently two WHO pre-licensed
OCVs available: Dukoral (Crucell, Leiden, Netherlands) and
Shanchol (Shantha Biotechnics Ltd., Basheerbagh, Hyderabad,
India). Both vaccines are given as two doses (7 and 14 days
apart respectively) and both require cold chain for transport.
They are safe and effective for a limited period of time.1
Outbreaks of cholera in refugee populations can have dramatic
impacts in terms of mortality and morbidity. Large-scale out-
breaks have been documented among Rwandan refugees in the
Democratic Republic of Congo in 1994,2 in refugee camps in
South Sudan in 20073 and among Somali refugees in Kenya in
2009.4 Preventative cholera MVCs have so far been limited or
restricted to small-scale interventions5–9 and their use still
debated. OCV has also been used in a preventative way in a com-
plex emergency (Aceh, Indonesia in 2005) and in an internally
displaced person camp (Darfur, Sudan, 2004).10
Since November 2011, Me´decins Sans Frontie`res (MSF) have
provided primary and secondary health care to an estimated
115 058 refugees and the surrounding host population (33 546
individuals) in Upper Nile State, South Sudan.11 The population
is divided over four camps: Jamam, Batil, Gendrassa and Doro
(Figure 1).
Cholera is endemic in South Sudan with annual outbreaks of
acute watery diarrhea reported between 2006 and 2012 in differ-
ent areas of the country.12–15 In July 2012, MSF, WHO and the
Ministry of Health conducted a risk assessment for the potential
impact of the introduction of cholera into the refugee camps in
Maban County. It was determined that the risk was high due to
a high intensity of transport of goods and traffic in the area. The
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population was also found to be highly vulnerable to cholera due
to their fragile health status and the inadequate water and sani-
tation conditions in the camps. This high perceived risk for a chol-
era outbreak in Maban County led to an agreement with the
Ministry of Health in September 2012 to conduct a mass vaccin-
ation campaign with OCV (Shanchol) in the four refugee camps
and their surrounding host populations.
Here, we report on the modus operandi of this MVC which, to
date, is the largest preventative OVC campaign implemented dur-
ing a humanitarian emergency. We also describe the logistic and
resource requirements related to two different vaccine delivery
strategies used during the campaign: 1) predominantly fixed
and 2) mobile/door-to-door.
Methods
The vaccination campaign started on 27 December 2012 and
ended on 7 February 2013. The campaign was conducted in two
rounds in order to administer two doses to recipients.
Target population and exclusion criteria
We targeted the refugee population living in the four refugee
camps and their surrounding host communities. The criteria to
include the host population were related to their proximity and
intense contact with the refugee camps’ population or their pres-
ence in the main markets. The total population in Maban County
at the time of vaccination was estimated to be 149 104 indivi-
duals. As OCV is developed for all individuals .12 months of
age, 96.2% (143 438/149 104) of the total population was
included as the target population.
The exclusion criteria for vaccination were children,12 months
and individuals whowere visibly ill at the time of vaccination or who
were excluded on the basis of medical advice. In these latter cases,
excluded individuals were given the opportunity to receive the vac-
cination at a later stage at any of MSF’s healthcare facilities.
Pregnant women were included in the vaccination campaign.16
Vaccine procurement
As two doses of OCV should be administered, 350 650 doses were
ordered (¼2×143 438 target population+10% additional buffer).
The vaccines arrived in insulated boxes weighing 140 kg per box,
each containing 12 600 vaccines. Each vaccine vial was equivalent
to one dose and had a volume of 16.8cm3. Vaccines were ordered
directly from the manufacturer Shantha Biotechnics Ltd.
(Basheerbagh, Hyderabad, India). All vaccines were air freighted
into Maban County due to the remoteness of this location in
South Sudan.
Figure 1. Map of the four refugee camps in the oral cholera vaccine (OCV) vaccination campaign, Maban County, South Sudan, December 2012 to
February 2013. This figure is available in black and white in print and in colour at Transactions online.
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Cold chain management
The Shanchol vaccine is determined to be medium stable for heat
exposure and has a Vaccine Vial Monitor (VVM) 14,meaning that it
can be kept for a period of 14 days at 378C. The vaccines were
transported in cold boxes and stored in refrigerators (2–88C).
Temperature control monitors were implemented in all the refrig-
erators in order to maintain the cold chain. On the day of vaccin-
ation, controlled temperature chain (CTC) was applied. In Jamam,
Gendrassa and Batil all vials required for one round of vaccination
were stored in cold boxes without ice-packs inside. In Doro, all
vials were stored in normal buckets without ice packs. These
were replenished twice a day with vaccines. Finally all VVMs on
vials were checked before administration to ensure the stability
of the vaccine.
Vaccination strategies and teams
We employed two vaccination strategies: 1) a predominantly fixed
strategy with outreach points in markets and in the periphery of
the camps and 2) amobile door-to-door strategy. These are sum-
marized in Table 1. In both strategies, the teams were composed
of community members (community workers and volunteers
from other NGOs). Each team received theoretical and practical
training with a session on how to conduct the vaccination.
The predominantly fixed strategy was used in Gendrassa,
Jamam and Batil. In each camp we established nine vaccination
teams at fixed points. The most suitable location was decided
together with the community leaders and the health authorities.
Outreach vaccination activities (with smaller mobile teams) were
organized to reach peripheral populations, the main markets and
individuals unable to walk to the fixed vaccination points (e.g. the
elderly). A vaccination card, which was issued during the first
round, had to be presented by each person when seeking the
second dose of vaccine. With this card there was an additional
voucher for soap distribution after the administration of the
second dose. The host population was vaccinated using the
mobile door-to-door strategy.
The mobile door-to-door strategy was used in Doro for both
the refugee and host population. As there were no fixed vaccin-
ation sites, the number of teams was decided based upon the
size of the target population. In total, 57 teams of three people
were deployed during the vaccination campaign. No vaccination
cards were used in this strategy based on previous experience
showing that cards are often lost during, between or after the vac-
cination campaign. Furthermore, we believed that their use would
reduce the simplicity and speed of the mobile door-to-door strat-
egy. In this strategy, the refugee population did not receive soap
with the administration of the second dose as these were already
included in the weekly kit distributed for camp residents. Vaccine
recipients from the host community received a bar of soap after
each dose.
Social communication and mobilization
Social mobilization started 1 week before the first round and a
small reminder was distributed several days before the second
round (Table 1). Contacts with the community leaders as well
with other NGOs and health authorities were established in
order to use all possible communication channels. The informa-
tion shared included the rationale behind the vaccination, basic
information about cholera and standard precautions such as
hygiene practices, as well as information about the vaccine, the
target group, the importance of the two doses regime and the
vaccination card, the immunization strategy and the side effects.
Table 1. Logistics and resource requirements related to a predominantly fixed andmobile strategy for mass oral cholera vaccination for refugees,
Maban County, South Sudan, December 2012 to February 2013
Predominantly fixed strategy Mobile strategy: door-to-door
Vaccination locations Jamam, Batil, Gendrassa Doro
Population type Refugee and host Refugee and host
Vaccination points Fixed sites plus mobile outreach Mobile
Vaccination card Yes No
Soap voucher Yes Only for host population
No. of vaccination sites 9 per location NA
No. of vaccination teams 9 per location 57
No. of vaccinators 184 (92 per location)a 386b
Supervision One medical supervisor per team One supervisor for each 3–4 teams
Team composition NGO staff and community health workers NGO staff and community health workers
Cold chain (CTC) Cold boxes, no ice packs Regular buckets, no ice packs
Social mobilization T-shirts, banners, verbal messages Verbal messages
CTC: controlled temperature chain; NA: not applicable.
a Part of the fixed team was performing outreach activities.
b Different team composition according to the location to vaccinate.
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Coverage data, adverse effect reporting and financial
estimates
In both strategies, data was collected on a daily basis using vac-
cination site tally sheets. These sheet listed information on the
number of individuals vaccinated by age group and gender. This
data was entered daily into an Excel spreadsheet (Microsoft
Excel 2010, Microsoft Corporation, Redmond, WA, USA) in order
to calculate daily administrative coverage numbers based on
available population data. Using the daily statistics, the delivery
strategies and the team allocations were reviewed to better tar-
get the areas reporting unsatisfactory vaccination coverage. For
the predominantly fixed strategy, the data from round one was
also used to change the planning for the second round, such as
increasing team’s capacity at the busiest vaccination sites from
round one or the re-prioritization of resources to certain larger
villages.
In order to monitor adverse effects, each vaccination team
was able to record any observed adverse effects in recently vacci-
nated individuals. Additionally, we established reporting of
adverse effects from vaccination at all health facilities in Maban
County.
Following the campaign we tried to estimate the costs per vac-
cinated individual by calculating the cumulative costs of vaccines
and human and logistical resources. The total expenses were
divided by the total number of vaccinated individuals in the
campaign.
Results
Vaccination coverage
Across all four refugee camps, 130 560 individuals were vacci-
nated during the first round of vaccination and 128 365 indivi-
duals were vaccinated during the second round (Supplementary
data). Taking into account the available population data, this
translated to a first round vaccination coverage for the refugee
population of above 84% in Doro, Jamam and Batil and 104%
in Gendrassa. The second dose achieved the same coverage as
the first dose. For the host population, the vaccination coverage
for the first dose was above 90% in Doro and Jamam and 53%
in Gendrassa and Batil. For the second round, the coverage was
above 79% in Doro and Jamam and above 70% in Batil and
Gendrassa (Figure 2). The results of the vaccination coverage sur-
vey will be communicated elsewhere.
Logistic and human resource requirements for both
vaccination strategies
Each team in the mobile door-to-door strategy vaccinated
between 500–700 individuals per day, while in the predominantly
fixed strategy an average of 250 individuals per hour received
OCV at each vaccination site. The mobile door-to-door strategy
required a higher number of people for implementation (386 indi-
viduals) compared to the predominantly fixed strategy which
required 184 individuals. However in the mobile door-to-door
strategy the teams worked 12 days (6 days each round) com-
pared to the teams in the predominantly fixed strategy who
worked approximately 29 days for the two rounds.
The average cost per dose administered ranged fromE3.32 for
the mobile door-to-door strategy to E4.68 for the predominantly
fixed strategy. These cost estimates exclude the costs for inter-
national staff. The main costs were attributed to the purchase
of the vaccines (E1.5/dose), the transport to difficult to access
areas of Maban County (air freight for the majority of supplies)
and the cold chain hardware. The cost per person vaccinated
varies from E7–E9. The difference in cost estimates between
strategies might be due to the existing availability of cold
chain materials for the mobile door-to-door strategy, as well as
the reduced transportation costs in this strategy as the target
population was lower (therefore less vaccines needed to be
transported).
In the predominantly fixed strategy, the choice was made to
use a card in order to confirm the vaccination status during the
coverage survey. Vaccination cards did not include the individual’s
name, only their age and gender, therefore during the second
round matching cards to the correct individuals was a challenge.
Also several individuals lost their cards between rounds and there
were misunderstandings about what the vaccination card was
andwhat the soap voucher was. In themobile door-to-door strat-
egy the vaccination card was not used resulting in less logistical
burden on the mobile teams. The risk of double counting was lim-
ited as the tally sheet reporting howmany peoplewere vaccinated
in a tent during the first round was used during the second round
matching the number of individuals per tent.
Reported adverse effects of OCV
Adverse effects were reported by 471/258 832 (0.18%) indivi-
duals, mainly during the first round. All the adverse effects were
of a minor nature such as nausea, vomiting, abdominal pain
and diarrhea. Thirty-five percent of individuals reporting adverse
effects sought care in the health centers and two people required
hospitalization for dehydration. The majority of the adverse
effects occurred in women (71.3%, 102/143) and in the age
group of 15–49 years old (47.1%, 67/142).
Logistic constraints
Some cold chain ruptures were reported due to freezing and
therefore 7350 vials were lost. One batch of vaccine doses arrived
in styrofoam trays and some vials in this tray demonstrated an
unusual change of VVM; the Shanchol vaccine has a VVM 14.
This means that the vaccine has a medium stability for heat
exposure: it can be kept for a period of 14 days at 478C and
90 days at a temperature of 258C. VVM at level 1 is the starting
point: the vaccine is useable if the expiry date has not passed. It
turns from level 1 to level 2 when the vaccine is exposed to heat
but it can be used. The VVM turns from level 1 to level 4 when the
endpoint is exceeded and the vaccine cannot be used anymore.
The VVM changed to level 4 in the part of the vial that was outside
the Styrofoam tray while the bottom part of the VVM remained at
level 2. Due to the unusual change in the VVM and the indication
of the level 4 which means that the vials reached their end point,
these vaccines were not used. All vaccines displaying this VVM
composition were discarded and destroyed.
The existing OCV vial has a metallic cap which is not user
friendly to open. It requires the use of scissors and during the vac-
cination campaign this slowed down the process. To make the
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vaccination process smooth and fast, one person in each team
was in charge of opening the vials. In addition, the single dose
vial occupies a large storage volume in the cold chain. This re-
sults in the need for high storage capacity (with cold chain) for
mass vaccination campaigns which is not always achievable in
humanitarian emergency settings.
Discussion
This vaccination campaign demonstrated that a MVC with two
doses of OCV is feasible in closed settings at high risk of cholera
introduction. Since the vaccination campaign was conducted,
no suspected cases of cholera have been reported in the refugee
and host populations in Maban County. This in itself is not evi-
dence that the vaccination campaign has been effective in
preventing cholera introduction.
There was a high vaccination acceptance among the refugee
population and they were eager to reach the fixed sites to receive
the vaccine. In contrast, in the host population the door-to-door
(mobile strategy) approach was better adapted to the context.
The two different strategies did not show significant differences
in terms of coverage and speed. The predominantly fixed strategy
took longer to complete the vaccination campaign because it was
applied in three camps consecutively (not simultaneously) while
the mobile door-to-door strategy was used in one camp.
Generally, the speed used to vaccinate one camp using the pre-
dominantly fixed strategy is the same as that reported for the
mobile door-to-door strategy. In future campaigns in closed set-
tings a mixed strategy, which employs fixed points and mobile
teams, would be likely to be the most effective.
The strategies employed for this OCV campaign did not signifi-
cantly differ from other MVCs conducted in closed settings for
other vaccine antigens. The predominantly fixed strategy enabled
vaccination of a higher number of people in a shorter period of
time and employed fewer human resources, but it had a geo-
graphical limit. The advantage of the mobile door-to-door
strategy was the ease with which we reached the whole target
population. It did, however, require large amounts of people to
reach every house in a reasonable period of time.
The single dose vaccine vial requires a high storage volume,
but was manageable because the campaign was done over a
2-month period allowing a phased storage and release of vaccine
vials. The vaccine was supplied for one vaccination round at a
time. However better adapted packaging could simplify the vac-
cination process and expand the use of OCV. At present two
doses are needed to reach an acceptable level of protection in
the individual. A single dose vaccine would facilitate the logistics
and administration of OCV in MVCs substantially. Moreover, it
would improve adherence to vaccination by the target population,
probably increase coverage levels in all target groups and allow
OCV to be given concomitantly with other vaccine antigens during
the same campaign. Studies in Kolkata, India, have shown that a
single dose of OCV stimulates a partial immunity response but it
still has to be demonstrated whether this response is sufficient to
protect against the disease.17
The high thermostability of Shanchol allowed the use of CTC at
field level and consequently reduced the cold chain needs. Studies
on efficacy and long term ambient temperature stability are
needed to guarantee that CTC can continue to be used in future
campaigns. More studies on vaccine efficacy under ambient tem-
perature and single dose long term protection are needed to
increase the use of OCV on a larger scale.
Also, the use of the vaccination card is frequently debated dur-
ing mass vaccination campaigns. Its use has an added value dur-
ing post-MVC surveys. In the case of Maban, the evidence of
vaccination for the coverage survey was absent in the Doro refu-
gee and host populations and, therefore, might need to be
considered for use in future.
Social mobilization has been essential to inform the population
about vaccination. The use of the community health workers who
already knew the camp proved to be a crucial positive aspect of
the campaign.
Figure 2. Administrative coverage of refugee camps and host populations during the oral cholera vaccine (OCV) vaccination campaign in Maban county,
South Sudan, December 2012 to February 2013.
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We must acknowledge that this OCV campaign was set up as a
means toprevent the introduction of cholera into an existing vulner-
able population in South Sudan. The systems established, therefore,
formonitoring and evaluationwere targeted specifically at ensuring
that the campaign reached its target population. We did not envi-
sion the MVC as a study and as such our documented experience of
this campaign with OCV has remained descriptive in nature. In
future campaigns it would be of use to have, for example, more
detailed financial recording systems to be able to better document
differences in cost estimates per person vaccinated.
Conclusion
In a large refugee population in South Sudan, mass vaccination
with OCV was feasible, accepted by the population and achieved
very high coverage. This outcome is very encouraging as using the
cholera vaccine during humanitarian emergencies, as an added
measure for reducing cholera related morbidity in vulnerable
populations, such as refugees and internally displaced persons,
has now become increasingly achievable.
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Supplementary data are available at Transactions Online (http://
trstmh.oxfordjournals.org/).
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